Your sleep tracker might be more honest than you are. A massive study reveals poor sleep rhythm—not sleep duration—is what ...

Across four prospective U.S. cohorts, 4.5% of those 18-49 years old met criteria for COPD, defined as spirometric airflow obstruction plus symptoms of cough, phlegm, and dyspnea or 10 or more ...

AI offers promise in the realm of chronic disease management, including diabetes, obesity, and PCOS, but must be approached ...

European regulators have given their backing to a new eco-friendly inhaler that could help curb health care’s climate impact.

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a narrow economic moat. Growth of existing products and new product launches should help offset ...

Urine VOCs are linked to COPD risk and inflammation in NHANES data, suggesting potential for non-invasive screening with strong diagnostic accuracy.

Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), succeeding in a Phase IIb trial but failing in a Phase III study.

Challenge invites proposals from startups who are focused on enhancing the quality of life for respiratory patients through environmentally friendly and accessible solutions ...

A study suggests that a single brain MRI can be used to predict a person's rate of aging across their whole body, which ...

UBC Okanagan researchers have developed a 3D bio-printed model that closely mimics the complexity of natural lung tissue, an innovation that could transform how scientists study lung disease and ...